Antiviral-HIV-1 Integrase Strand Transfer Inhibitors

Antiviral HIV-1 integrase strand transfer inhibitors (INSTIs) are a key therapeutic drug class of antiretroviral agents used for the treatment and prevention of human immunodeficiency virus type 1 (HIV-1) infection Members of this class, such as dolutegravir, bictegravir, and cabotegravir, serve as core components in first-line combination regimens for managing HIV-1 and as agents for pre-exposure prophylaxis

Antiviral HIV-1 integrase strand transfer inhibitors (INSTIs) are a key therapeutic drug class of antiretroviral agents used for the treatment and prevention of human immunodeficiency virus type 1 (HIV-1) infection Members of this class, such as dolutegravir, bictegravir, and cabotegravir, serve as core components in first-line combination regimens for managing HIV-1 and as agents for pre-exposure prophylaxis

These agents selectively bind to the active site of the virally encoded integrase enzyme, specifically preventing the strand transfer reaction necessary for integrating synthesized viral DNA into the host cell genome

These agents selectively bind to the active site of the virally encoded integrase enzyme, specifically preventing the strand transfer reaction necessary for integrating synthesized viral DNA into the host cell genome

By halting viral replication, they lower plasma HIV-1 RNA levels and allow reconstitution of immune function

By halting viral replication, they lower plasma HIV-1 RNA levels and allow reconstitution of immune function Members of this class, such as dolutegravir, bictegravir, and cabotegravir, serve as core components in first-line combination regimens for managing HIV-1 and as agents for pre-exposure prophylaxis